Quarterly ResultAug 12, 2026, 08:18 AM
Century Therapeutics Q2 Loss $34.6M; CNTY-813 IND on Track 4Q 2026
AI Summary
Century Therapeutics reported a net loss of $34.6 million for the second quarter of 2026, with a net loss per share of $(0.17). The company maintained a strong financial position with $197.2 million in cash, cash equivalents, and investments as of June 30, 2026, extending its cash runway into Q1 2029. Significant pipeline progress includes CNTY-813's IND submission remaining on track for Q4 2026 following FDA alignment, and CNTY-308 expected to enter the clinic in 2026.
Key Highlights
- CNTY-813 IND submission for type 1 diabetes therapy remains on track for Q4 2026.
- CNTY-308, a CAR-iT cell therapy, is expected to enter the clinic in 2026.
- Cash, cash equivalents, and investments totaled $197.2 million as of June 30, 2026.
- Company estimates cash runway into Q1 2029.
- Net loss for Q2 2026 was $34.6 million, compared to $32.5 million for Q2 2025.
- Research and development expenses decreased to $19.6 million in Q2 2026 from $26.9 million in Q2 2025.
- Net loss per common share was $(0.17) for Q2 2026, compared to $(0.38) for Q2 2025.
Price Impact
More from IPSC